CITY OF INDUSTRY, Calif., Oct. 18 /PRNewswire-FirstCall/ -- U.S. Biodefense, Inc. and AntiCancer, Inc. announced today that they have formed a collaboration to research, develop and commercialize novel approaches on utilizing human neural crest stem cell and their potentials in human transplantation.
Stem cell research will increase the understanding of the nervous system and may allow the development of treatments for currently incurable brain diseases and spinal cord injuries. The collaboration encourages stem cell research for the study of neural crest stem cells as potential transplantable tissue for the repair of injury such as that sustained during traumatic brain injury or stroke, for the repair of pathological processes such as those seen in the neurogenetic diseases glutaric acidemia (Type I) or Leigh's disease, or for repair of neurodegenerative processes such as those seen in Parkinson's or Alzheimer Diseases.
Director of Research, Dr. Cyndi Chen, Ph.D. stated, "The agreement makes it possible for us to establish neural crest stem cells as a candidate for development in therapies and treatments. Collaborating with Anti-Cancer will present a very promising future for both sides and for the medical community."
"We are very excited to embark on our second collaboration with the AntiCancer, Inc., given AntiCancer's commitment to both basic science and pre-clinical research in an ongoing effort to unravel the complex underpinnings of diseases," said David Chin, President and CEO of U.S. BioDefense, Inc.
About AntiCancer, Inc. (www.anticancer.com)
AntiCancer, founded in 1984 and based in San Diego, is also developing new drugs based on genetic engineering that target cancer-specific metabolic defects. AntiCancer's small-animal fluorescence imaging technology is uniquely enabling for high-throughput in vivo drug discovery and evaluation for cancer and other diseases. The company is also developing diagnostics for diseases including cancer. The company is also actively developing genetic and stem-cell approaches to cancer and other diseases.
About U.S. Biodefense, Inc. (www.usbiodefense.com)
U.S. BioDefense is a Department of Defense central contractor that researches, develops, and commercializes leading-edge bio and biodefense technology. U.S. BioDefense, Inc. is focused on transferring, researching, and commercializing groundbreaking technology from Universities, Research Labs, Fortune 500 Companies, and Government Agencies.
Certain statements in these interviews and news releases may constitute "forward looking" statements within the meaning of Section 21E of the Securities Exchange Act of 1934. Such forward looking statements involve risk, uncertainties, and other factors, which may cause the actual results, performance, or achievement expressed or implied by such forward looking statements to differ materially from the forward looking statements. Certain statements contained in the interviews are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements involve numerous risks and uncertainties, including, but not limited to, risks and uncertainties pertaining to development of U.S. Biodefense's products and services and markets for such products and services, the timing and level of customer orders, competitive products and service, changes in economic conditions and other risks and uncertainties. Although the companies believe the statements are reasonable, they can give no assurance that such expectations will prove correct. The companies caution that any forward-looking statements contained herein are not a guarantee of future performance and that actual result may differ materially.
U.S. BioDefense, Inc.
David Chin, 626-961-0562
U.S. Biodefense, Inc.